Cerus jumps on raising annual product guidance, Q2 revenue beat

Cerus

04/08/2021 10:11

** Shares of biomedical products company  CERS.O  up as much
as 15.01% at $5.9 premarket, among top pct gainers among
Nasdaq-listed stocks  
    ** CERS raises annual product revenue guidance to a range of
$118 million to $122 million from the prior guidance of $110
million to $114 million
    ** Q2 revenue of $$37.8 mln beat Refinitiv IBES estimates of
$31.5 mln  urn:newsml:reuters.com:*:nASA02GJX
    ** Says product revenue growth benefited from increased
demand for its INTERCEPT platelet products in the U.S, with
broad-based demand from blood centers across the country
    ** Stock down ~25% YTD, as of last close 

 (Reporting by Rithika Krishna in Bengaluru)
 ((Rithika.Krishna@thomsonreuters.com;))